Published in Blood Cells Mol Dis on December 11, 2006
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood (2011) 1.09
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Adv Virol (2012) 0.89
Feline leukemia virus long terminal repeat activates collagenase IV gene expression through AP-1. J Virol (1999) 0.87
EBV reactivation as a target of luteolin to repress NPC tumorigenesis. Oncotarget (2016) 0.77
Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. Oncotarget (2015) 0.76
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J (1986) 6.82
Epstein-Barr virus infection. N Engl J Med (2000) 5.93
Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst (1999) 4.94
Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med (1995) 4.62
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med (1989) 3.76
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci (2003) 3.67
The effect of sodium butyrate on histone modification. Cell (1978) 2.73
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Ganciclovir. N Engl J Med (1996) 2.19
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol (2004) 2.11
NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 1.92
Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood (1993) 1.82
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep (2002) 1.47
Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res (2000) 1.45
X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol (2001) 1.33
In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg Pathol (1994) 1.33
Virally targeted therapies for EBV-associated malignancies. Oncogene (2003) 1.29
Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ (1998) 1.28
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood (2002) 1.26
Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother (2001) 1.26
Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol (1987) 1.25
Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol (1994) 1.18
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol (1999) 1.14
Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis (2001) 1.10
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis (1998) 1.10
Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer (1983) 1.08
Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol (2001) 1.06
Re: detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst (2000) 1.05
Monoclonal Epstein-Barr virus genomes but lack of EBV-related protein expression in different types of gastric carcinoma. Histopathology (1994) 1.03
Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res (2003) 1.03
The role of EBV in post-transplant malignancies: a review. J Clin Pathol (2000) 1.02
Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology (1980) 0.99
Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA (1988) 0.98
Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol (1990) 0.95
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology (2002) 0.91
Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch Virol (1984) 0.87
Demethylation of the Epstein-barr virus origin of lytic replication and of the immediate early gene BZLF1 is DNA replication independent. Brief report. Arch Virol (1999) 0.85
Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res (2006) 1.64
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype. Blood Cells Mol Dis (2013) 1.54
Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol (2003) 1.53
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Retracted HIC1 regulates tumor cell responses to endocrine therapies. Mol Endocrinol (2009) 1.42
Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J (2005) 1.38
Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J (2002) 1.34
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J (2004) 1.29
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood (2002) 1.26
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res (2011) 1.15
Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood (2006) 1.15
Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis (2008) 1.12
Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets (2003) 1.10
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood (2011) 1.09
Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer (2009) 1.08
Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem (2006) 1.08
Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Cancer Biol Ther (2007) 1.05
Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem (2002) 1.05
Protein kinase C delta is required for survival of cells expressing activated p21RAS. J Biol Chem (2007) 1.04
Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. Cell Growth Differ (2002) 1.03
Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis (2005) 1.03
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate (2012) 1.00
Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol (2011) 0.98
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors. Endocr Relat Cancer (2011) 0.97
Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci (2010) 0.95
Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol (2009) 0.94
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. Br J Haematol (2013) 0.93
Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol (2009) 0.93
Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics (2008) 0.93
Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. BMC Cancer (2014) 0.91
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology (2002) 0.91
Drosophila female sterile (1) homeotic is a multifunctional transcriptional regulator that is modulated by Ras signaling. Dev Dyn (2008) 0.91
Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett (2007) 0.91
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs (2008) 0.90
Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther (2007) 0.90
A functional promoter polymorphism of the δ-globin gene is a specific marker of the Arab-Indian haplotype. Am J Hematol (2012) 0.90
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol (2005) 0.90
Butyrate histone deacetylase inhibitors. Biores Open Access (2012) 0.90
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal (2008) 0.89
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Adv Virol (2012) 0.89
T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides (2011) 0.89
Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol (2003) 0.87
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol (2010) 0.87
Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol (2012) 0.86
Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des (2006) 0.86
Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo. Blood Cells Mol Dis (2011) 0.85
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication. Virology (2003) 0.84
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2013) 0.84
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) (2010) 0.83
Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism. Virology (2005) 0.83
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2012) 0.83
Novel short chain fatty acids restore chloride secretion in cystic fibrosis. Biochem Biophys Res Commun (2006) 0.82
Desensitization of the PDGFbeta receptor by modulation of the cytoskeleton: the role of p21(Ras) and Rho family GTPases. Exp Cell Res (2002) 0.81
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol (2011) 0.81
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
Identification of LTR-specific small non-coding RNA in FeLV infected cells. FEBS Lett (2009) 0.80
Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. J Cell Physiol (2004) 0.80
Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol (2014) 0.79
Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells. Nucleic Acid Ther (2013) 0.79
Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics (2008) 0.78
The role of Ras in T lymphocyte activation. Cell Signal (2002) 0.78
A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood (2014) 0.78
Effects of divalproex sodium on hemoglobin level. Blood Cells Mol Dis (2009) 0.78
Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis. Nucleic Acid Ther (2013) 0.78
Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma. Clin Lymphoma Myeloma (2006) 0.78
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol (2013) 0.77
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Anticancer Res (2008) 0.77
Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy. J Pediatr (2003) 0.77
Short-term toxicity study of ST-20 (NSC-741804) by oral gavage in Sprague-Dawley rats. Toxicol Pathol (2011) 0.75
Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope (2002) 0.75